 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
GeneCentric Licenses UNC IP for Lung Cancer Subtyping Dx, Signature Linked to anti-VEGF Rx Response
September 05, 2012
GeneCentric Licenses UNC IP for Lung Cancer Subtyping Dx, Signature Linked to anti-VEGF Rx Response
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thermo Fisher Contacted Life Tech in 2011 about Possible Acquisition; Document Discloses Other Bidders
May 22, 2013 / GenomeWeb Daily News - NIH Team Presents Findings from Fungi-focused Study of Skin Microbiome
May 22, 2013 / GenomeWeb Daily News - Mount Sinai, Rensselaer Harness Clinical Medicine, R&D, Computing Synergies
May 22, 2013 / GenomeWeb Daily News - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter - With Exclusive License to Marker, Empire to Launch Neuroendocrine Prostate Cancer Dx This Year
May 22, 2013 / Pharmacogenomics Reporter